Recent advances in the management of atypical hemolytic uremic syndrome

Clin Adv Hematol Oncol. 2012 Aug;10(8):537-9.
No abstract available

MeSH terms

  • ADAM Proteins / genetics
  • ADAM Proteins / metabolism
  • ADAMTS13 Protein
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Atypical Hemolytic Uremic Syndrome
  • Biomarkers / metabolism
  • Blood Platelets / drug effects
  • Blood Platelets / pathology
  • Complement Activation / drug effects
  • Complement Inactivating Agents / therapeutic use*
  • Complement System Proteins / genetics*
  • Complement System Proteins / immunology
  • Diagnosis, Differential
  • Disease Management
  • Hemolytic-Uremic Syndrome / complications
  • Hemolytic-Uremic Syndrome / diagnosis
  • Hemolytic-Uremic Syndrome / genetics
  • Hemolytic-Uremic Syndrome / therapy*
  • Humans
  • Mutation
  • Plasma Exchange
  • Platelet Count
  • Purpura, Thrombocytopenic / diagnosis
  • Purpura, Thrombocytopenic / genetics
  • Purpura, Thrombocytopenic / therapy*
  • Renal Insufficiency / etiology

Substances

  • Antibodies, Monoclonal, Humanized
  • Biomarkers
  • Complement Inactivating Agents
  • Complement System Proteins
  • eculizumab
  • ADAM Proteins
  • ADAMTS13 Protein
  • ADAMTS13 protein, human